鲁亮, 张汉群, 曹辉, 冯志宇, 袁佳, 李馨, 李勇. 贝伐珠单抗联合培美曲塞治疗复发转移性宫颈癌患者的临床观察[J]. 中国肿瘤临床, 2019, 46(2): 83-85. DOI: 10.3969/j.issn.1000-8179.2019.02.067
引用本文: 鲁亮, 张汉群, 曹辉, 冯志宇, 袁佳, 李馨, 李勇. 贝伐珠单抗联合培美曲塞治疗复发转移性宫颈癌患者的临床观察[J]. 中国肿瘤临床, 2019, 46(2): 83-85. DOI: 10.3969/j.issn.1000-8179.2019.02.067
shu
Lu Liang, Zhang Hanqun, Cao Hui, Feng Zhiyu, Yuan Jia, Li Xin, Li Yong. Clinical observation of bevacizumab combined with pemetrexed for patients with recurrent metastatic cervical cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(2): 83-85. DOI: 10.3969/j.issn.1000-8179.2019.02.067
Citation: Lu Liang, Zhang Hanqun, Cao Hui, Feng Zhiyu, Yuan Jia, Li Xin, Li Yong. Clinical observation of bevacizumab combined with pemetrexed for patients with recurrent metastatic cervical cancer[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 46(2): 83-85. DOI: 10.3969/j.issn.1000-8179.2019.02.067
shu

贝伐珠单抗联合培美曲塞治疗复发转移性宫颈癌患者的临床观察

Clinical observation of bevacizumab combined with pemetrexed for patients with recurrent metastatic cervical cancer

    摘要
  • 摘要:
      目的  观察贝伐珠单抗联合培美曲塞治疗复发转移性宫颈癌的近期疗效及不良反应。
      方法  回顾性分析2014年1月至2016年12月贵州省人民医院收治的32例复发转移性宫颈癌患者的临床资料, 所有患者均使用贝伐珠单抗联合培美曲塞, 21天为1个周期, 行4~6个周期治疗, 并评价疗效及评定不良反应级别。
      结果  32例宫颈癌患者中无完全缓解患者, 部分缓解7例(21.9%)、疾病稳定19例(59.4%)、疾病进展6例(18.7%), 有效率为21.9% (7/32), 疾病控制率为81.3% (26/32)。32例患者常见不良反应程度均较轻, 可以耐受。
      结论  贝伐珠单抗联合培美曲塞方案治疗复发转移性宫颈癌患者近期疗效好, 其不良反应可耐受, 远期疗效有待进一步的研究。

     

    Abstract:
      Objective  To observe the short-term efficacy and side effects of bevacizumab combined with pemetrexed for the treatment of recurrent and metastatic cervical cancer.
      Methods  The clinical data of 32 patients with recurrent metastatic cervical cancer admitted to the Department of Oncology, Guizhou Provincial People's Hospital between January 2014 and December 2016 were retrospectively analyzed. All patients were treated with bevacizumab plus pemetrexed. In the 21-day cycle, chemotherapy was administered for 4 to 6 cycles. The efficacy and grade of adverse reactions were evaluated.
      Results  Of the 32 patients with cervical cancer, 0 had complete remission, 7 (21.9%) had partial remission, 19 (59.4%) had stable disease, and 6 (18.7%) had disease progression. The effective rate was 21.9% (7/32) and the disease control rate was 81.3% (26/32). The 32 patients had mild common adverse reactions, which can be tolerated.
      Conclusions  Bevacizumab combined with pemetrexed has good short-term effects for patients with recurrent and metastatic cervical cancer, and its side effects can be tolerated. The long-term efficacy warrants further study.

     

    • HTML全文
    • 参考文献(13)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回